$ALGN

A federal appeals court reversed a lower court ruling, allowing antitrust claims against Align Technology (ALGN) to proceed. The case involves allegations related to dental aligners, specifically Invisalign. This decision may impact ALGN's legal and financial outlook.

Stock futures dip as European debt concerns weigh on markets. Nvidia rises 0.6% on AI infrastructure spending, while Intel falls 4% amid TSMC-Terafab collaboration talks. Several companies see significant premarket moves: ALVO +8%, CBRS +4.5%, DKNG +4.6%, EL +2.8%, HOG +5.7%, PCVX +56%, PTC +36%, RXO +20%, TSM +1.6%, TXRH +2.2%, WFC +2.2%. US economic data and Fed speakers are on the calendar.

Stifel raised AMD's price target to $700 from $635, maintaining a Buy rating. Other analysts adjusted targets for ON, GNRC, WTFC, LAD, ALGN, PLNT, CRDO, DTE, and RS. AMD closed at $633.91 on Friday.

Wall Street analysts issued updates on several companies. Estee Lauder (EL) was upgraded to Outperform with a $108 target, Harley-Davidson (HOG) to Buy with a $33 target, Microsoft (MSFT) to Buy with a $665 target, and Wells Fargo (WFC) to Overweight with a $102 target. Align Technology (ALGN) was downgraded to In Line with a $155 target, and HubSpot (HUBS) to Market Perform. Bitcoin (BTC) saw volatility, trading around $86,120 after a Citigroup $113,000 target.

U.S. stock futures fell on Monday. Align Technology (ALGN) dropped 2.8% after a downgrade and price target cut by Evercore ISI. Other stocks like Roze AI (RZAI), United Microelectronics (UMC), and Group 1 Automotive (GPI) also declined in pre-market trading.

Evercore ISI downgraded Align Technology (ALGN) to In Line, citing weak demand and slowing growth for Invisalign products. The firm set a $155 price target, lowered revenue estimates, and noted a 11% quarter-over-quarter decline in monthly active users. ALGN's Q2 2026 earnings beat expectations but stock fell due to softer systems revenue and guidance concerns.

Align Technology (ALGN) stock fell 1.7% in pre-market trading after Evercore ISI downgraded it from 'Outperform' to 'In Line'. The company has 10 buy, 5 hold, and 1 sell ratings. ALGN reported mixed Q2 2026 results with record Clear Aligner revenues but a 10.8% drop in Systems and Services revenue. Q3 guidance and full-year outlook disappointed, contributing to a 9.4% decline over the past month. The stock trades below its 52-week high but above its low, with a fair value estimate of $203.07.

Envista, Henry Schein, Align Technology, and Dentsply Sirona reported Q2 earnings. Henry Schein beat revenue and EPS estimates, while Align met revenue expectations but missed guidance. Dentsply Sirona's revenue declined but topped estimates. Stocks reacted negatively post-earnings, with Align down 20.1% and Dentsply down 30.6%.

Envista (NYSE:NVST) reported Q2 revenue of $730.5M, up 7.1% YoY, beating estimates. Align Technology (NASDAQ:ALGN) reported $1.06B, up 4.3% YoY, missing revenue guidance. Henry Schein (NASDAQ:HSIC) reported $3.46B, up 6.7% YoY, beating estimates. Stocks are down since reporting.

Align Technology (ALGN) reported quarterly earnings exceeding expectations but lowered Q3 revenue guidance. Management cited inflation and delayed elective dental treatments as factors. Analysts forecast 2029 revenues of $4.7B and earnings of $721.2M, with potential upside or downside depending on demand recovery and competition. The company presented at the 2026 Global Healthcare Conference to discuss its strategy and risks.